1.
Blood
; 143(2): 178-182, 2024 Jan 11.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37963262
RESUMEN
ABSTRACT: Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.